Dawn Hill

Dawn Hill is a seasoned clinical operations leader with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as the Chief Clinical Operations Officer at BridgeBio since January 2018, Dawn oversees clinical operations for QED Therapeutics' skeletal dysplasia programs. Prior roles include Senior Vice President and Vice President of Clinical Operations at OncoMed Pharmaceuticals, as well as Executive Director of Clinical Operations at ProTrials Research. Dawn has also held significant positions at Omnicare, Clinimetrics, Chiron Corporation, and Roche, contributing to various aspects of clinical and business operations. Dawn holds a BS in Biochemistry from the University of California, Davis, and completed education at Baden Senior School in Germany.